Different strategies have been developed to perform haploidentical stem cell transplantation (haplo HSCT) without graft manipulation. [1] [2] [3] Investigators from the Johns Hopkins University pioneered the use of post-transplantation cyclophosphamide (PT-Cy) after a T-cell replete haploidentical bone marrow infusion. In the Baltimore scheme tacrolimus (FK), with mycophenolate mofetil (MMF), was used to prevent GvHD and a host vs host (HVG) reaction. 4 FK is a calcineurin inhibitor that is almost 100-fold more potent than cyclosporine A (CyA) in its inhibitory activity and more active in clinical trials. [5] [6] [7] In this retrospective study, we analyzed 100 patients grafted with haplo HSCT with PT-Cy and receiving FK or CyA.
From April 2009 until April 2013 we analyzed 100 consecutive patients with hematological malignancies undergoing T-cell replete haploidentical transplantation with PT-Cy at two institutions (Institut Paoli Calmettes in Marseille, France and Humanitas Cancer Center in Rozzano, Italy).
Patients were candidates for haploidentical transplantation (haplo HSCT) if they met the following criteria: (1) lack of HLA-matched related or unrelated donor; (2) previous history of disease relapse after several chemotherapeutic lines or following a previous autologous or allogeneic transplantation; (3) refractory to conventional salvage chemotherapy and thus candidates for an auto-allo strategy consisting of high-dose melphalan (200 mg/m 2 ) followed by haplo; and (4) high-risk patients in first or further CR. The comorbidity index of each patient was calculated using the hematopoietic cell transplantation comorbidity index system. 8 The conditioning regimen consisted of Cy 14.5 mg/kg on days -5 and -6, fludarabine 30 mg/m 2 from day -6 to day -2 and low-dose TBI (2 Gy) on day -1. The GvHD prophylaxis consisted of Cy 50 mg/kg administered on days +3 and +4, FK or CyA and MMF. FK (1 mg) was administered as a continuous infusion until discharge and was converted to an oral formulation thereafter. Doses were adjusted to obtain serum levels between 10 and 20 ng/mL. CyA was dosed at 3 mg/kg as a continuous infusion until discharge and was converted to an oral formulation thereafter. CyA doses were modified to obtain serum levels between 100 and 200 ng/mL. MMF was administered at 15 mg/kg per os three times per day until day +35 and was then stopped. FK, CyA and MMF were started on day +5. FK and CyA were tapered from day +100 to day +180. Supportive care was previously described. 5 Acute GvHD (aGvHD) was graded according to the Keystone criteria, 9 and chronic GvHD (cGvHD) was graded following the NIH criteria. 10 We performed a retrospective analysis of all the consecutive patients to explore the outcome using FK or CyA as GvHD prophylaxis. PFS, overall survival (OS), GvHD-free/relapse-free survival (GRFS), relapse incidence, no-relapse mortality (NRM), aGvHD and cGvHD cumulative incidence were calculated. Survival endpoints were defined according to EBMT statistical guideline criteria. Relapse/progression incidence was also estimated using death as a competing event. Survival curves were estimated using the Kaplan − Meier model, and differences between the groups were estimated using a log-rank test. A P ⩽ 0.05 was considered to be statistically significant. All analyses were performed using STATA software (Stata Corp. 2013. Stata Statistical Software: Release 13. College Station, TX, USA: Stata Corp LP).
Patient and transplant characteristics are reported in Table 1 . Forty-three patients received FK and 57 received CyA. Five variables were significantly different between these groups: CMV serology, source of stem cell, hematopoietic cell transplantation comorbidity index, number of CD34+ cells infused and disease distribution, even if the disease risk index was not significantly different. Considering the FK and CyA groups, the engraftment rate was not significantly different. The median time to achieve full donor chimerism was 33 days (range 30-109) and 30 days (range 15-100). The incidence of grade II − IV aGvHD was 33% in the FK group and 48% in the CyA group (P = 0.1). The cumulative incidence of grade III − IV aGvHD was 2% and 9% (P = 0.176), respectively. Two patients, both in the CyA group, died from grade IV aGvHD. The cumulative incidence of cGvHD was 8% in the CyA group and 13% in the FK group (P = 0.9). The cumulative incidence for all patients with moderate-severe cGvHD was 2%.
For all the patients, the 2-year PFS and OS were 57% and 66%, respectively (Figures 1a and b) . The 2-year PFS and OS was 53 vs 60% (P = 0.4) and 65 vs 65% (P = 0.7) in the FK and CyA groups, respectively (Figures 1c and d) . The 2-year GRFS was 45% for all the patients, with no significant differences between the FK and CyA groups (42 vs 49%, respectively, P = 0.5). The 2-year relapse incidence was 28 and 12% in the FK and CyA group, respectively (P = 0.08; Figure 1e ). The 2-year NRM was 16% in the FK group and 14% in the CyA group (P = 0.7; Figure 1f ). In the univariate analysis, only disease status (CR vs not CR) impacted the PFS, OS and relapse incidence. The patients were regrouped into three cohorts: FK+bone marrow (BM) (n = 42), CyA+BM (n = 14), and CyA+PBSC (n = 43) (one patient was excluded because received FK+PBSC). The 1-year NRM was not different between the groups (17% vs 14% vs 15%, respectively, P = 0.8), nor was the cumulative incidence of aGvHD and cGvHD. On the basis of the assumption that the group CyA +BM, which was small in number, could dilute the effects of the CyA+PBSC group, we re-analyzed the outcome comparing two groups: FK+BM (as reference arm) and CyA+PBSC (as competitor arm). The results are shown in Table 2 . No significant differences were observed between the reference and competitor arms. Similarly, the 2-year GRFS was not different between the two groups (43% vs 49%, respectively, P = 0.6).
The results from this retrospective study suggest that there are no major differences between FK and CyA in T-cell replete haplo-SCT and PT-Cy. In a nationwide survey conducted in Japan, the use of FK506 rather than CyA was beneficial not only for the prevention of GvHD but also for the survival of patients undergoing unrelated donor-HSCT. 11 Furthermore, in a large retrospective study from the Center for International Blood and Marrow Transplant Research analyzing the risk factors for developing aGvHD, prophylaxis with FK significantly reduced the risk for developing aGvHD after both HLAid sibling and unrelated transplantation. 12 In this study, we analyzed 100 patients receiving a nonmyeloablative conditioning regimen with PT-Cy and FK (standard group) or CyA both starting from day +5. The three groups were not completely balanced because, significantly more patients in the FK group received BM and had a lower comorbidity index. We did not find any difference in terms of engraftment, aGvHD, cGvHD, NRM and survival. In the univariate analysis, only the disease status before haplo was significantly associated with survival. As a result, we can conclude that CyA works, as well as FK, after a haploidentical transplantation with nonmyeloablative conditioning regimen. According to the univariate analysis, the source of stem cells (BM vs PBSC) was not associated with different survival. However, this could be biased, because all the patients but one in the FK group, were infused with BM, while the CyA patients received BM (14 patients) or PBSC (43 patients). Considering the FK+BM group as a reference arm in this analysis and the CyA+PBSC group as the experimental arm, we did not find major differences either aGvHD or cGvHD rates. In addition, there was a no significant reduction in the time to achieve safe ANC levels (P = 0.09), nor was there a significantly higher grade 3 − 4 incidence in the CyA+PBSC arm (P = 0.09). Although it could be speculative, the reduction of relapse with CyA and PBSC is an interesting point to develop, considering that the higher number of T cells infused may mediate a stronger anti-tumor effect.
Some years ago, we developed a composite end-point associating relapse and development of cGvHD in order to capture quality of life of surviving patients. 13 More recently, GRFS, including both relapse, development of severe aGvHD or cGvHD, and death, is a new composite end point that recognizes the weight of clinical events in the survival of patients. 14 In this analysis, the 2-year GRFS is 45%, without differences in FK or CyA.
Although this study has potential biases associated with a retrospective analysis and the conclusions should be taken with caution, we conclude that replacement of FK by CyA in the Baltimore scheme did not appear to be detrimental for patients after T-cell replete haploidentical transplantation with PT-Cy. Abbreviations: aGvHD = acute GvHD; cGvHD = chronic GvHD; NRM = norelapse mortality; OS = overall survival; PLT = platelets.
